{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976450",
  "id": "02976450",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250804",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250804/pdf/06mhjx83rpyzls.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n\n- **Structure:** Two-tranche placement with free attaching listed options (IBXO terms).  \n- **Total raised:** AUD 3.5M (Tranche 1: AUD 0.675M; Tranche 2: AUD 2.8M subject to shareholder approval).  \n- **Key terms:**  \n  - Issue price: AUD 0.015/share (10% discount to 10-day VWAP).  \n  - One free listed option (exercise price AUD 0.04, expiry 13 Dec 2027) per new share.  \n  - Lead manager fee: 6% + 26.25M unlisted options (AUD 0.04 exercise, 3-year term).  \n- **Use of proceeds:** HER2 Breast Cancer Phase 2 trial initiation, prostate/ovarian Phase 1 programs, IP filings, and MRI/AI collaborations.  \n- **Timetable:**  \n  - Trading resumes: 4 Aug 2025.  \n  - Tranche 1 settlement/allotment: 5\u20136 Aug 2025.  \n  - EGM: 18 Sep 2025 (Tranche 2 approval).  \n  - Tranche 2 settlement/allotment: 19\u201322 Sep 2025.  \n\n*Omitted: Director commentary, background on technology.*",
  "usage": {
    "prompt_tokens": 1802,
    "completion_tokens": 290,
    "total_tokens": 2092,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-03T23:49:40.202935"
}